AstraZeneca Pharmaceuticals LP
1 MedImmune Way
2746 articles about AstraZeneca Pharmaceuticals LP
Six supplements commonly taken to improve heart health and lower high cholesterol were ineffective when compared to AstraZeneca’s Crestor (rosuvastatin) and placebo.
Sanofi and AstraZeneca won European approval for the first preventative RSV treatment for a broad population of newborns and infants.
Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
The European Commission has approved Beyfortus® for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants during their first RSV season.
Seven pharma CEOs announce new joint action to accelerate net zero healthcare
CEOs from AstraZeneca, GSK, Merck KGaA, Novo Nordisk, Roche, Samsung Biologics and Sanofi announced joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
AstraZeneca released data Wednesday morning from two studies in breast cancer: the Phase III CAPItello-291 trial studying capivasertib and the Phase II SERENA-2 trial studying camizestrant.
AstraZeneca reported Tuesday that its Phase III MESSINA trial hit one primary endpoint but missed the other. The study was evaluating Fasenra in eosinophilic esophagitis.
In a Phase III trial comparing Novartis’ experimental iptacopan against AstraZeneca's Soliris and Ultomiris in paroxysmal nocturnal hemoglobinuria, iptacopan demonstrated superiority.
The FDA greenlit AstraZeneca's tremelimumab in combination with its checkpoint inhibitor Imfinzi as a treatment for patients with unresectable hepatocellular carcinoma.
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the fourth annual Cancer Community Awards (C2 Awards).
EVUSHELD RECEIVES HEALTH CANADA APPROVAL FOR TREATMENT OF COVID-19
AstraZeneca's Evusheld™ (tixagevimab and cilgavimab), a long-acting antibody combination has received a Notice of Compliance from Health Canada for the treatment of mild to moderate COVID-19 in adults and adolescents (≥12 years of age weighing at least 40 kg).
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
LogicBio® Therapeutics, Inc., a pioneering clinical-stage genomic medicine company, announced that it has entered into a definitive agreement under which AstraZeneca Rare Disease will acquire LogicBio.
AstraZeneca is acquiring LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts to braoden its portfolio in genomics and rare diseases.
The announcement follows a subgroup analysis of the Phase III SOLO3 trial which showed patients treated with Lynparza saw a 33% greater risk of death than controls who received standard chemotherapy.
AstraZeneca has decided to drop the hypercholesterolemia candidate AZD8233 through to Phase III, despite meeting its Phase IIb primary efficacy endpoint, its partner Ionis announced Friday.
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
AstraZeneca and Merck announced that LYNPARZA has been approved in China as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency -positive status.
Press Release: CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Beyfortus® for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants during their first RSV season.
AstraZeneca's rare disease subsidiary Alexion posted positive late-stage results from a potential complementary treatment for paroxysmal nocturnal hemoglobinuria.
It was a busy weekend at ESMO 2022 with Merck, Astellas, Seagen, Regeneron, AstraZeneca and GRAIL all presenting data from their various cancer programs.
AstraZeneca presented data showing Imfinzi and Tagrisso boosted survival chances for patients in different forms of lung cancer at ESMO on Monday.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
Detailed positive results from an interim analysis of the DESTINY-Lung02 Phase II trial showed ENHERTU® demonstrated clinically meaningful tumor responses in previously-treated patients with HER2-mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.